Every material Form 8-K Hawkins filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Hawkins reported fiscal 2025 second-quarter results for the quarter ended September 29, 2024, with sales up 4% to $247.0 million and net income of $24.1 million. Growth came from the Water Treatment segment, which rose 23% on acquisitions, while Industrial and Health and Nutrition sales declined. The company described the quarter as a record for revenue, gross profit, operating income, net income and diluted EPS.
Diluted EPS was $1.16, up $0.06, or 5%, from $1.10 a year earlier.
Water Treatment sales rose $23.6 million, or 23%, to $124.5 million; Industrial sales fell 9% to $89.9 million.
Operating income was $33.7 million; adjusted EBITDA, a non-GAAP measure, was $46.3 million, up 12%.
The company paid down $30 million on its line of credit in the quarter and reported a leverage ratio of 0.65x.
At its July 31, 2024 annual meeting, Hawkins shareholders elected all eight director nominees, ratified Grant Thornton LLP as independent auditor for the fiscal year ending March 30, 2025, and approved executive compensation on an advisory basis. The filing's voting results are administrative and contain no financial figures. The filing's header lists Item 5.02, but its content reports votes under Item 5.07.
Eight directors elected; Faulconbridge had 2,003,313 votes withheld and Spethmann had 141,036
Grant Thornton LLP ratified: 17,402,747 for, 545,877 against, 34,096 abstain
Say-on-pay approved on an advisory basis: 14,988,501 for, 842,981 against, 68,061 abstain
Hawkins reported record first-quarter fiscal 2025 results for the three months ended June 30, 2024, with net income of $28.9 million, or $1.38 per diluted share, up from $1.12 a year earlier. Sales rose 2% to $255.9 million, driven by Water Treatment growth from acquisitions, while Industrial and Health and Nutrition sales declined. For shareholders, profit growth was strong, though the company's total debt rose to $134.0 million after acquisitions and net borrowings.
Net income was $28.9 million, or $1.38 per diluted share, versus $23.4 million, or $1.12 per diluted share, a year earlier.
Sales were $255.9 million, up 2%; Water Treatment sales rose 25% to $117.2 million, while Industrial sales fell 15% to $103.2 million.
Gross profit rose 24% to $64.7 million, and adjusted EBITDA rose 25% to $50.9 million.
Total debt was $134.0 million at quarter end, and the leverage ratio was 0.84x; the company closed two acquisitions in the quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Hawkins filing is on SEC EDGAR ↗. 8-K briefs of other companies →